Related Experiment Video
Updated: May 21, 2026
05:16
Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
SEOM guidelines for gastrointestinal stromal sarcomas (GIST)
Andrés Poveda1, Fernando Rivera, Javier Martín
1Servicio de Oncología Médica, Fundación Instituto Valenciano de Oncología, Valencia, Spain. apoveda@fivo.org
Summary
Gastrointestinal stromal tumors (GISTs) are the most common digestive tract tumors. Targeted therapy with imatinib has significantly improved median survival for advanced GIST patients from 18 to over 60 months.
Area of Science:
- Oncology
- Gastroenterology
- Molecular Biology
Background:
- Gastrointestinal stromal tumors (GISTs) represent the most frequent mesenchymal neoplasms of the digestive tract.
- GISTs serve as a paradigm for multidisciplinary oncological management.
- The integration of various specialties has driven advancements in GIST understanding and treatment.
Purpose of the Study:
- To highlight the multidisciplinary approach in managing GISTs.
- To emphasize the impact of targeted therapy on patient outcomes.
- To advocate for specialized care centers and clinical trial participation.
Main Methods:
- Review of GIST management strategies.
- Analysis of the role of imatinib in solid tumor treatment.
- Discussion of multidisciplinary team collaboration.
Main Results:
- Imatinib is the first effective molecular therapy for solid tumors.
- Median survival for advanced GIST patients increased from 18 to over 60 months post-imatinib introduction.
- Multidisciplinary care has significantly advanced GIST understanding.
Conclusions:
- GIST therapy planning requires a multidisciplinary approach.
- Care in reference centers specializing in sarcomas and GISTs is recommended.
- Participation in clinical trials is advisable for optimal patient management.